Beyond Air (NASDAQ:XAIR) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.47) by 21.28 percent. This is a 19.35 percent decrease over losses of $(0.31) per share from the same period last year.
JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $17
JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the price target from $19 to $17.